Key Points Collaboration and license revenue (GAAP) for Q2 2025 was $8.1 million but missed Q2 2025 GAAP revenue estimates by $0.11 million. Net loss (GAAP) widened to $15.8 million, with increased ...

Xilio anticipates nominating development candidates for its PSMA program (ATACR format), CLDN18.2 program (ATACR format) and STEAP1 program (SEECR format) in the third quarter of 2025, fourth quarter ...

Biotech veteran brings 20+ years of operations, facility design and manufacturing expertise Eric Hanson Industry veteran named Senior Director of Life Sciences at CRB Kansas City, Mo., Aug. 14, 2025 ...

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look ...

The biotechnology industry is split between two very different types of companies. On one side are the large, blue-chip leaders like Amgen Inc. (ticker: AMGN), Gilead Sciences Inc.

Gilead wins US approval for Yeztugo HIV prevention shot, but its $28,000 price sparks access concerns despite near-perfect ...

A wave of factory closures is reshaping regional economies, displacing skilled laborers and weakening supply chains.

Wall Street and the Fed will get more insight next week on inflation’s temperature and the economy. The government will ...

Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly ...

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

Analysts lift targets for Gilead as HIV sales surge and Yeztugo launch gains traction, supporting a stronger full-year ...